2021
November 9, 2021
Contract Pharma
Orphan Drug Development Trends by Dirk Lange, CEO of Selexis SA & President and CEO of KBI Biopharma
July 13, 2021
BioProcess International
Selexis and KBI to advance Immatics program toward IND by Millie Nelson
June 2, 2021
Contract Pharma
Selexis SA Appoints Hoffmann-Hecht CBO by Kristin Brooks
March 23, 2021
The Science Advisory Board
Selexis, Tallac to advance novel immunotherapies by The Science Advisory Board Staff
March 18, 2021
BioWorld
Other news to note for March 18, 2021 by BioWorld Staff
March 19, 2021
The Pharma Letter
Selexis signs license deal with SpyBiotech on HCMV vaccine program by The Pharma Letter Staff
March 16, 2021
Contract Pharma
Selexis, Pandion Enter Antibody Service Agreement by Kristin Brooks
March 9, 2021
Drug Discovery News
An agreement to advance BITR2101 by Mel J. Yeates
2020
May 19, 2020
Contract Pharma
Selexis Makes Scientific and Operational Promotions by Contract Pharma Staff
February 11, 2020
Genetic Engineering & Biotechnology News
Selexis Cell Line Development Strategies by John Morrow Jr., Ph.D.
2019
September 21, 2019
The Center for Biosimilars
First Dornase Alfa Biosimilar Approved and Launched in Russia by The Centers for Biosimilars Staff
April 11, 2019
Bipharma-Reporter.com
Selexis’ biologic platform generates first-ever approved Soliris biosimilar by Maggie Lynch
April 11, 2019
BioProcess International
World’s first Soliris biosimilar launched in Russia by Dan Stanton
January 14, 2019
BioProcess International
Selexis and Agenus expand immune-oncology cell line deal by BPI Staff
2018
December 27, 2018
BioProcess International
TeneoBio expands cell banking deal with Selexis by Dan Stanton
October 9, 2018
BioProcess International
Hoba (cell) banks on Selexis to advance neuropathic pain program by Dan Stanton
July 11, 2018
Biopharma-Reporter.com
Selexis and Symphogen Expand Partnership to Process two mAbs by Ben Hargreaves
April 19, 2018
BioPharma-Reporter.com
Selexis Says $2M Investment Will Speed Up Cell Bank Delivery Time by Flora Southey
February 28, 2018
FierceBiotech
Xencor extends collaboration with Selexis to advance bispecific antibody programs by Angus Liu
2017
November 1, 2017
Genetic Engineering & Biotechnology News
Weighing Protein Expression Levels with Cell Growth by Angelo DePalma, Ph.D.
June 27, 2017
BioProcess International
Selexis Announces Commercial License Agreement with Takeda for the Development of Fusion Proteins by BPI Contributor
May 8, 2017
Biopharma-Reporter.com
Selexis’ Swiss investment in mammalian cell lines by Flora Southey
February 21, 2017
BioPharma-Reporter.com
Sanofi hires Selexis SA for three cell line development deals by Gareth Macdonald
2016
October 10, 2016
Contract Pharma
Cell Line Development Trends: How CHO cell line development technologies are improving biologics development from early phase to IND by Igor Fisch, Ph.D.
October 7, 2016
BioProcess International
BioProcess International Announces Winners of the 2016 BioProcess International Awards by BPI Staff
September 12, 2016
BioPharma-Reporter.com
Selexis to triple cell line capacity on back of increased demand by Dan Stanton
April 18, 2016
BioProcess International
Cancer Immunotherapies: Fulfilling the Promise of Protein and Cell Therapies by Angelo DePalma
April 15, 2016
Genetic Engineering & Biotechnology News
GEN Roundup: How to Improve Cell-Line Productivity by GEN Staff Writer
2015
May 11, 2015
Genetic Engineering & Biotechnology News
Ligand Buys Another 15 Biologics Programs from Selexis for $4M by GEN Staff Writer
